
Isis Pharmaceuticals and AstraZeneca have announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal …

AstraZeneca’s lung cancer therapy Iressa has been approved by the FDA – four years after the company pulled it from the …

Brand consultancy The Partners has appointed creative director Peter Henshaw to lead its creative offerings for the agency’s health team. …

AstraZeneca vice president James Ward-Lilley and Takeda’s chief financial officer François-Xavier Roger are both exiting their respective companies and moving …

Teva’s investigational biologic for the treatment of inadequately controlled asthma in patients with elevated blood eosinophils, Cinquil, has been accepted …

Briggs Morrison who joined AstraZeneca in 2012 and played an instrumental part in defending its takeover by Pfizer, is abruptly …

AstraZeneca is embarking upon a joint venture that will involve the building of a new $125 million small-molecule plant in …
AstraZeneca has appealed to the government to put ‘urgent transitional measures’ in place to make sure patients can access innovative …

AstraZeneca’s investigational drug AZD9291 is continuing to impress, with results announced at cancer conference ASCO building on its previous ‘unprecedented’ …

AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …

A ‘senior male employee’ of Otsuka Pharmaceuticals “potentially brought the industry into disrepute” by plying a female healthcare professional with …

Amgen has ended its agreement with AstraZeneca to develop a new biologic for psoriasis, because of the likelihood of ‘restrictive …

AstraZeneca is spending around $285 million on a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The …

The FDA has warned that a class of type 2 diabetes drugs manufactured by several big pharma firms could cause …

An investigational immuno-oncology drug combination from AstraZeneca has shown promise in its most recent trial, although concerns over its side …